制定风险阈值以辅助已稳定使用csDMARD的系统性自身免疫性风湿病患者血液学、肝脏和/或肾脏药物不良反应的风险分层监测:一项RAND/UCLA适宜性方法共识研究
共识认为,当5年预测风险≤10%时,6个月血检间隔适宜;当风险>10%时,3个月间隔适宜,为已稳定使用csDMARD的成人SARD患者提供了风险分层监测阈值。
要点
- 5年预测风险≤10%时,6个月血检间隔获共识认为适宜。
- 5年预测风险>10%时,3个月血检间隔获共识认为适宜。
- 该阈值用于已稳定使用csDMARD至少1年的成人SARD患者监测。
核心结论
- 达成了一项风险阈值,用于辅助已稳定使用csDMARD的成人SARD患者进行风险分层监测。
研究设计与样本
- 采用RAND/UCLA适宜性方法共识研究,由英国风湿病学会csDMARD指南工作组成员参与。
- 专家对9种5年预测风险(5%至25%)场景下血检间隔的适宜性进行1至9分评分。
主要发现
- 所有场景均达成共识。
- 当5年预测风险≤10%时,6个月血检间隔获共识认为适宜。
- 当5年预测风险>10%时,3个月血检间隔获共识认为适宜。
关键数值与推荐
- 共识定义:中位评分≥7且至多6名专家评分<7时,认为该间隔适宜。
- 5年预测风险≤10%:6个月血检间隔适宜。
- 5年预测风险>10%:3个月血检间隔适宜。
临床怎么用
- 可根据患者5年预测风险选择血检监测间隔:≤10%用6个月,>10%用3个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore how appropriate different intervals between monitoring blood tests are considered in relation to the risk of clinically significant adverse drug reactions in adults prescribed conventional synthetic DMARDs (csDMARDs) for ≥1 year for systemic autoimmune rheumatic diseases (SARD). METHODS: A RAND/UCLA Appropriateness Method consensus study was undertaken. Members of the BSR csDMARD guideline working group who manage adults with SARD participated. Experts rated the extent to which intervals between blood tests were appropriate using Likert-type scales with responses from 1 (totally inappropriate) to 9 (totally appropriate) for nine scenarios with 5-year predicted risk of discontinuing treatment due to abnormal monitoring blood tests from 5% to 25%. Median score and the number that voted 1-3 (inappropriate), 4-6 (unsure) and 7-9 (appropriate) were calculated for every interval in each scenario. Scenarios for which agreement could not be reached in the first round were recirculated, enclosing individual round 1 response and the panel median score. Consensus that an interval was appropriate for a scenario was reached where the median panel score was ≥7 and up to six experts rated <7. The results were discussed with patient and public involvement members and experts. RESULTS: Twenty-one of the 27 invitees participated. They comprised 11 consultants/GPs, five specialist nurses, three pharmacists and two rheumatology specialty trainees. Consensus was reached for all scenarios. Six- and three-monthly blood tests were agreed as appropriate when the predicted risk was ≤10% and >10% over 5 years, respectively. CONCLUSION: A threshold to aid risk-stratified monitoring during established csDMARD treatment was agreed for adults with SARD.
引用
- Ablewhite J, Nakafero G, Almayahi A, et al. The development of a risk threshold to aid risk stratified approach to monitoring for haematological, hepatic and/or renal adverse drug reactions during established cs DMARD treatment for systemic autoimmune rheumatic diseases: a RAND/UCLA Appropriateness Method consensus study. Rheumatology (Oxford). 2026. PMID: 41632485. doi:10.1093/rheumatology/keag031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。